

## Response to Reviewer's Comments

1. case report is novel and the authors should discuss about the Abemaciclib-induced prevalence of diarrhea and fatigue in comparison to palbociclib and ribociclib.  
Any adverse of hepatotoxicity reported in the patient ???.

Reply:

Thank you for your valuable comments. The description has been added in the Treatment and clinical course section (please see page 5) and Discussion section (please see page 6).

2. In the MRI, I noticed the abemaciclib plus letrozole treatment mediated attenuation of the brain metastases and the contrast effect. The assessment indicated a therapeutic effect equivalent to partial response.

Reply:

Thank you for your insightful comments. The description in the relevant section has been corrected (please see page 5 and Figure 2B legend)

3. Is the patient postmenopausal female ?? mention in the manuscript

Reply

Thank you for your pertinent comments. The description has been added in the Chief complaints section (please see page 4).

4. Enhance the discussion with the following articles <https://aacrjournals.org/clincancerres/article/26/20/5310/82934/A-Phase-II-Study-of-Abemaciclib-in-Patients-with> <https://pubmed.ncbi.nlm.nih.gov/32694159/> Use endnote/Mendly for referencing Line by line proof reading is potentially required.

Reply

The indicated references are listed in No 9; an error in the year of publication has been corrected. The response rate for brain metastasis in hormone receptor-positive HER2-negative breast cancer reported in reference 9 have also been added in the Discussion section (please see page 6).

5. Several sentences need rewriting to make the readers comfortable when

reading this.

Reply

The manuscript has been proofread by a Native speaker according to Reviewer's instructions, and we have made minor changes such as rephrasing.